Henry Ford Health

Henry Ford Health Scholarly Commons
Neurosurgery Articles

Neurosurgery

1-21-2021

Cerebral microcirculation in glioblastoma: A major determinant of
diagnosis, resection, and drug delivery
Tavarekere N. Nagaraja
Henry Ford Health, TNagara1@hfhs.org

Ian Y. Lee
Henry Ford Health, ilee1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/neurosurgery_articles

Recommended Citation
Nagaraja TN, and Lee IY. Cerebral microcirculation in glioblastoma: a major determinant of diagnosis,
resection and drug delivery. Microcirculation 2021.

This Article is brought to you for free and open access by the Neurosurgery at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Neurosurgery Articles by an authorized administrator of Henry
Ford Health Scholarly Commons.

Received: 16 November 2020

|

Accepted: 12 January 2021

DOI: 10.1111/micc.12679

REVIEW ARTICLE

Cerebral microcirculation in glioblastoma: A major determinant
of diagnosis, resection, and drug delivery
Tavarekere N. Nagaraja
Department of Neurosurgery, Henry Ford
Hospital, Detroit, MI, USA
Correspondence
Tavarekere N. Nagaraja, Department of
Neurosurgery, Henry Ford Hospital, 2799
West Grand Blvd., Detroit, MI 48202,
USA.
Email: tnagara1@hfhs.org
Funding information
Henry Ford Hospital, Grant/Award
Number: A20050

| Ian Y. Lee
Abstract
Glioblastoma (GBM) is the most common primary brain tumor with a dismal prognosis.
Current standard of treatment is safe maximal tumor resection followed by chemotherapy and radiation. Altered cerebral microcirculation and elevated blood-tumor
barrier (BTB) permeability in tumor periphery due to glioma-induced vascular dysregulation allow T1 contrast-enhanced visualization of resectable tumor boundaries.
Newer tracers that label the tumor and its vasculature are being increasingly used
for intraoperative delineation of glioma boundaries for even more precise resection.
Fluorescent 5-aminolevulinic acid (5-ALA) and indocyanine green (ICG) are examples
of such intraoperative tracers. Recently, magnetic resonance imaging (MRI)–based
MR thermometry is being employed for laser interstitial thermal therapy (LITT) for
glioma debulking. However, aggressive, fatal recurrence always occurs. Postsurgical
chemotherapy is hampered by the inability of most drugs to cross the blood-brain
barrier (BBB). Understanding postsurgical changes in brain microcirculation and permeability is crucial to improve chemotherapy delivery. It is important to understand
whether any microcirculatory indices can differentiate between true recurrence and
radiation necrosis. LITT leads to peri-ablation BBB opening that persists for several
weeks. Whether it can be a conduit for chemotherapy delivery is yet to be explored.
This review will address the role of cerebral microcirculation in such emerging ideas in
GBM diagnosis and therapy.
KEYWORDS

5-ALA, brain drug delivery, brain tumor, contrast enhancement, EOR, GTR, indocyanine green,
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to be poor.2,3 The current standard of care consists of surgery followed
by external beam radiotherapy (EBRT) and temozolomide (TMZ).4

High-grade gliomas (HGGs), including Glioblastoma (GBM), are the most
1

For GBM, the most common malignant glioma, the median survival is

common primary malignant brain tumor in adults. Despite intense re-

14–16 months with a 2-year survival rate of about 30% following stan-

search over the last 50 years, the survival of patients with HGG, a group

dard of care treatment.5,6 With maximal cytoreductive surgery consist-

comprising WHO grade III and IV malignant glioma tumors, continues

ing of resection of the contrast-enhancing lesion up to 98%, survival can

Abbreviations: 5-ALA, 5-aminolevulinic acid; ADC, apparent diffusion coefficient; BBB, blood-brain barrier; BTB, blood-tumor barrier; DCE-MRI, dynamic contrast-enhanced MRI; DSA,
digital subtraction angiography; DWI, diffusion-weighted imaging; EBRT, external beam radiotherapy; EOR, extent of resection; FLAIR, fluid-attenuated inversion recovery; GBM,
glioblastoma; GTR, gross total resection; HGG, high-grade glioma; iCEUS, intraoperative contrast-enhanced ultrasound; ICG, indocyanine green; ICG-VA, ICG-videoangiography; iMRI,
intraoperative MRI; iUS, intraoperative ultrasound; LITT, laser interstitial thermal therapy; MRI, magnetic resonance imaging; NPV, negative predictive value; PFS, progression-free
survival; PPV, positive predictive value; TIFP, tumor interstitial fluid pressure; TMZ, temozolomide; WHO, World Health Organization.
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be increased by approximately six months in both primary and recurrent
7,8

Thus, it is the imaging modality of choice to localize the presence

Unfortunately, the prognosis is particularly poor; progres-

of a suspected or confirmed GBM because of its sensitivity to soft

sion inevitably occurs, with 6-month progression-free survival (PFS)

tissue contrast, as well as to tumor-induced mass effect. 26 Hydrogen

conditions.

of 5–15%. Limiting treatment options, nearly all other approved and

nucleus/water proton in body fluids and tissues is the MR active nu-

experimental drugs have shown no positive effects in glioma therapy.

cleus and used in clinical MRI. Since water exhibits high signal in-

Molecular and genetic analyses have led to better disease stratification,

tensity on T2-weighted images, and GBMs have high levels of free

but not to effective therapies.9,10 Maximal resection of contrast-en-

water, T2-weighted images are used to visualize them. Conventional

hancing tumor followed by radiation and chemotherapy according to

techniques employed for vascular imaging include spin echo and

the Stupp protocol (EBRT/TMZ followed by metronomic TMZ) until

gradient echo sequences. In general, spin echo imaging uses radi-

evidence of recurrence is the only approved first line of treatment for

ofrequency pulse combinations at 90° and 180° pulses of inflowing

newly diagnosed GBM. Indices of survival being directly proportional

protons. Gradient echo sequences are usually acquired with an

to the extent of resection (EOR), efforts are ongoing to maximize the

initializing radiofrequency pulse followed by a refocusing gradient

surgeon's ability to identify the tumor margins during resection.11

pulse, both at a given flip angle. These sequences can be supple-

GBM is highly vascularized tumors demonstrating angiogenesis and

mented with pre-saturation or gradient moment rephasing to visual-

vascular co-opting to derive blood supply and energy to their proliferat-

ize the flowing protons as either signal void (black blood imaging) or

ing and infiltrative regions. Thus, brain microvasculature plays a crucial

signal enhancement (bright blood imaging). They also provide excel-

role in sustaining GBM and, as a result, is also a therapeutic target.12-17

lent contrast between the tissue and the vessels and, thus, can be

Angiogenesis leads to leaky vasculature compared to the normal brain

used to visualize vascular patency and any occlusions. Despite the

microvasculature that exhibits extremely low permeability to most

utility of T2 imaging in tumor visualization, there are pathological

blood-borne substrates. This property has been exploited in identifying

conditions in which even the high T2 hyperintensity may be insuf-

tumor margins via gadolinium-based, T1 contrast-enhanced MRI.18,19

ficient for accurate tumor detection. Although T1-weighted imaging

With the absence of radiation and excellent soft tissue contrast, MRI

shows higher signal-to-noise ratio in fat, tumor water demonstrates

is the preferred technique for brain tumor visualization for its local-

low signal intensity on T1. Enhancement agents (contrast agents) are

ization.20 Delineation of tumor boundaries is a pre-surgical necessity

then introduced to selectively affect the T1 and T2 relaxation times

because tumors in or near eloquent regions, for example, Broca's area,

in tumors to facilitate accurate tumor detection. Use of MR contrast

require additional precautions during surgery. In addition, extravascu-

agents provides an additional level of vascular information. Unlike

lar gadolinium contrast provides the most efficient approach that can

computed tomography contrast agents wherein the enhancement is

be repeated over time to identify changing tumor margins due to dis-

directly due to the concentration of the agent used, in MRI the ef-

ease progression or treatment. Recently, MRI has been supplemented

fects of the contrast agent used are measured. The most commonly

with other tracer techniques that further enhance real-time tumor vi-

used MRI contrast agents are gadolinium chelates.

sualization during surgery and aid in maximal cytoreductive resection.

MRI findings usually demonstrate an embedded mass with low

Fluorescent 5-aminolevulinic acid (5-ALA)21 and indocyanine green

signal intensity on T1-weighted images and high signal intensity

(ICG)22 are examples of such intraoperative tracers that are approved

on T2-weighted images. It is also characterized by irregular blood

for clinical use. In addition, intraoperative ultrasound (iUS) and its vari-

flow, internal cystic areas, areas with hemorrhagic foci (high T1

ation viz., intraoperative contrast-enhanced US (iCEUS) provide other

signal intensity), necrosis, peri-tumoral vasogenic edema, and sig-

methods for glioma visualization during surgery.23

nificant mass effect such as ventricular compression, typical of

Several other intraoperative brain tissue visualization and eval-

space-occupying tumors. However, conventional MRI is limited in

uation techniques such as Raman spectroscopy, optical coherence

its ability to determine type and grade of brain tumors, but ad-

tomography, neurophysiological monitoring, stereotactic navigation,

vanced MRI techniques, such as perfusion weighted imaging, may

functional MRI, whole brain tractography, and diffusion tensor im-

provide more physiologic information, potentially including glioma

aging are also employed to aid in efficient tumor debulking while

grading. 27 In addition, diffusion-weighted imaging (DWI) and its

sparing the normal brain tissue. 24,25 However, this review will focus

derivative apparent diffusion coefficient of water (ADC) are often

on techniques that are primarily reliant on glioma microvascular flow

used as surrogate markers of treatment response and tumor cel-

(for delivering tracers), BBB/BTB permeability alterations (facili-

lularity. 28 It has also been shown that dynamic contrast-enhanced

tating extravasation of contrast agents and fluorescent tracers), or

MRI (DCE-MRI) data can be processed to produce sophisticated,

endothelial metabolic alterations (aiding in preferential tracer accu-

quantitative, model selection maps of tumor segmentation based

mulation in tumor).

on vascular function in both preclinical models and clinical cases
of GBM. 29,30 Recently, several novel dynamic contrast-enhanced

2
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(DCE) MRI biomarkers to measure tumor interstitial fluid pressure
(TIFP), peri-tumoral flux and tumor cellularity have been described
in preclinical models. 31-33

MRI has the highest degree of fidelity in the diagnosis of GBM and

The multi-planar structural data acquired by conventional

is widely used for identifying the location and size of brain tumors.

MRI using T1-weighted, T2-weighted, and gadolinium-enhanced

|
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sequences play a central clinical role in diagnosis, grading, and in

debulking.43 Thus, despite the high cost, iMRI has become an indis-

monitoring treatment effects. It also has some limitations regard-

pensable tool in glioma surgery due to its ability to identify GBM

ing the biological specificity of the underlying signals. T2-weighted

vascular features and tumor tissue status. 25

dependent signal hyperintensity is dominated by tissue water content, and traditional T1 contrast enhancement reflects a non-specific increase in BBB permeability. Invasive and infiltrative GBM

3
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components not accompanied by edema or BBB opening can evade
detection by proton MRI. Diagnosis can be further confounded by

5-ALA is a prodrug preferentially metabolized by glioma cells that

treatment-induced effects that somewhat limit the prognostic ca-

allows direct, real-time visualization of pathologic tissue through

pacity of this type of imaging. Although gadolinium contrast is al-

fluorescence under 400–410 nm blue light. 21 Its exact mechanism

most always used to measure T1-weighted contrast, the use of such

is unclear, but via heme metabolic pathways tumor cells preferen-

agents is contra-indicated in cases with compromised kidney func-

tially accumulate the fluorescent reaction product protoporphyrin

tion.34 Poor renal clearance of gadolinium in these cases is related to

IX than in the surrounding normal cells. Although not directly re-

the development of nephrogenic systemic fibrosis or nephrogenic

liant on glioma microvascular flow or permeability abnormalities,

fibrosing dermopathy. Iron-based, blood pool contrast agents such

endothelial proliferation in glioma is presumed to play a major role

as ferumoxytol can be an alternative under such circumstances.

in tumor-specific accumulation of 5-ALA. The European Medicines

Compared to the lower average molecular weights of gadolini-

Agency officially authorized 5-ALA for use in glioma in 2007 and it

um-based contrast agents (eg, Magnevist = 938 Da), ferumoxytol

was approved in the United States in 2017. The prodrug is usually

has a molecular weight of 731 kDa.35 Its large size confers feru-

given orally at least 4–6 h before surgery to achieve peak tumor ac-

moxytol with imaging advantages like prolonged blood pool phase

cumulation. However, 5-ALA alone does increase EOR by itself while

and delayed intracellular uptake.36 Its long duration of intravascular

also increasing PFS. A phase II randomized trial showed that tradi-

space occupancy allows acute, high-resolution imaging of vascular

tional white light microscopy-based resection achieved 6-month PFS

space and delayed imaging of BBB disruption. In addition, studies

of 21% compared to 41% in 5-ALA-based resection.44 Significantly

have suggested that a combination of gadolinium and ferumoxy-

more EOR and PFS was also achieved with the use of 5-ALA

tol imaging can assist in differentiating between radiation necrosis

(18 months and 97%) compared to white light (6 months and 85%)

However, it needs to

in another study.45 It can also be used in conjunction with iMRI with

be noted here that use of ferumoxytol as a MR contrast agent is

contrast enhancement. When used in combination, 5-ALA can help

considered as off-label use. Other research has shown that tumor

localize MRI-invisible tumor tissue that is associated with an intact

microvascular quantification using MRI-based vessel size imaging

BBB. Thus, the two techniques are mutually complementary and

38

augment EOR when used together. Therefore, experts recommend

and, based on ADC alterations, in determining isocitrate dehydroge-

using 5-ALA in conjunction with iMRI (Figure 1) which increases EOR

nase (IDH) mutation status.39 Specific point mutations of the genes

significantly. 21 In support of this, 5-ALA alone led to total resection

encoding IDH 1 or 2 suggest GBMs that are associated with a more

in 46% of cases, whereas the addition of iMRI resulted in total re-

favorable outcome. Thus, determining IDH mutation status has im-

section in 74% of the cases.42 With its ease of application, ability to

and pseudo-progression in recurrent GBM.

37

can be potentially of use in noninvasive grading of glioma severity

portant implications in glioma prognosis.

40

seamlessly combine with iMRI and high tumor-specificity, 5-ALA is

Due to its preferred status as the imaging modality of choice in

considered the gold standard in intraoperative glioma visualization.

GBM diagnosis, it is not surprising that intraoperative MRI (iMRI)
has found applications in GBM surgery. It was first used by Black
et al. in 1997 to treat intracranial lesions.41 Since then it has become

4
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a part of the neurosurgical instrumentation to determine the presence of residual tumor. One of the great advantages of iMRI is that

Indocyanine green videoangiography (ICG-VA) is a near-infrared

it compensates for changes in brain morphology after craniotomy

range fluorescent marker used for intraoperative real-time assess-

and dural opening that can make relating to pre-surgical tumor loci

ment of flow in cerebrovascular surgery. 22 ICG has a positive pa-

difficult. Improvements in image quality and the availability of new

tient safety profile and is well tolerated in clinically required doses.

MR sequences have co-evolved with the use iMRI. iMRI is also used

It provides high spatial and temporal resolution and is extensively

during surgery to update contrast-dependent neuronavigation to

used in visualizing cerebral aneurysm repair and vessel grafting.

confirm tumor tissue shift due to cerebrospinal fluid loss and debulk-

ICG is given as an intravenous injection and binds to plasma pro-

ing.11 Its utility is evident by data from studies that have compared

teins and remains intravascular. With a plasma half-life of 3–4 min,

EOR in cases that were iMRI-aided to those that were not. The addi-

repeat bolus injections of ICG can be made for continuous vessel

42

monitoring. ICG binds to plasma proteins and turns into a blood pool

Gross total resection (GTR) also increased with the addition of iMRI.

agent with a short half-life despite its small size (775 Da). This fea-

Another study reported that GTR and overall survival were better

ture facilitates repeated injections at quick intervals to visualize the

and postsurgical complications were lower after iMRI-aided tumor

temporal phases of microvascular flow, viz., arterial, capillary and a

tion of iMRI increased EOR from about 58% to 71% in one study.

4 of 9
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F I G U R E 1 (A) Preoperative MRI T1+
gadolinium contrast (Magnevist) depicting
right frontal contrast-enhancing lesion. (B)
Intraoperative MRI T1+ contrast depicting
gross total resection of all enhancing
tissue. (C) View through operative
microscope with blue light demonstrates
residual fluorescence, though not as
avid as the majority of the tumor. (D)
Intraoperative MRI T2 fluid-attenuated
inversion recovery (FLAIR) sequence,
likely representing residual non-enhancing
lower grade tumor cells. (Reproduced with
permission from:Haider SA et al. Journal
of Neuro-Oncology. 2019;141(3):507–515.
https://doi.org/10.1007/s11060 -01803061-3)

combined arteriovenous phase due to dye recirculation. In its basic

vasculature. A high dose of ICG was delivered ~24 h before surgery,

use, ICG-VA provides low cost, useful, real-time qualitative and

leading to extravasation and accumulation of the tracer within the

quantitative information regarding cerebral blood flow in the visual

tumor allowing real-time intraoperative tumor identification to op-

field. The addition of digital subtraction angiography (DSA) enhances

timize surgical resection.47 It was observed that ICG accumulation

22

in tumor tissue was stable between 6 and 48 h after administration

ICG is often used in transplantation surgery to test the patency of

allowing a broad timeframe for surgical planning. ICG-VA has been

grafted blood vessels, in repairing brain aneurysms and to visualize

also used to identify the venous drainage pattern and collateral cir-

ischemic regions during such procedures. However, its application in

culations during tumor resection for possible venous sacrifice to

the study of the vascular pathophysiology in central nervous system

predict and minimize the potential side effects.46 Larger clinical trials

tumors and its potential utility in their surgical management is still

that include survival and quality of life measures are needed to make

limited. Recently, however, several studies are exploring ICG-VA as

the ICG-VA technique, as well as its potential combination with iMRI,

a tool in brain tumor resection. One study examined the feasibil-

more widely applicable in GBM resection.

ICG-VA capability, but is an expensive, labor-intensive procedure.

ity of ICG-VA in 71 brain and spinal tumor subtypes, including 14
cases of glioma.46 This study included the addition of a novel FLOW
800 algorithm integrated with the surgical microscope. This algorithm calculates fluorescence intensities in the exposed areas based

5 | FLU O R E S C E I N A N D I NTR AO PE R ATI V E
CO NTR A S T- E N H A N C E D U LTR A S O U N D

on the average arbitrary intensity units detected by the camera and
reconstructs maps of maximal fluorescence intensities and of delay

Fluorescein has been found to be useful in glioma surgery due its

times, producing semiquantitative cerebral blood flow estimates.

accumulation in tumors with increased vascular permeability.48 It

It was noted that pre-surgical imaging helped plan the surgery and

resembles the MR contrast agents in this respect, but requires so-

postsurgical imaging aided in estimating local hypoperfusion and

phisticated intraoperative fluorescence microscopy for its localiza-

associated risks. Several patients received multiple ICG injections

tion. Although under clinical trials, but currently not approved by

with no apparent negative side effects. The ability of ICG to bind to

Food and Drug Administration in the United States, fluorescein has

plasma proteins and remain intravascular in normal blood vessels has

been shown to increase tumor debulking in GBM with 83% GTR in

been exploited in a “Second Window ICG” technique for GBM resec-

the fluorescein group (n = 47) compared to 55% in the non-fluores-

tion that utilizes the inherently increased permeability of the tumor

cein group (n = 33); this efficacy was also seen in median survival

|
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F I G U R E 2 Pre- (A) and post-laser ablation (B) MR images in recurrence in left thalamic GBM. Note the peri-ablation gadolinium contrast
enhancement in B. The panel (C) shows the temperature map from MR thermometry. The intraoperative MR thermometry map was used
to precise definition of ablation margins and to spare maximum possible, normal peri-tumoral brain tissue. This image was generated
while using a Visualase LITT system (Medtronic, Inc., Minneapolis, MN). It uses a saline-cooled diode laser with a near-infrared (980 nm)
wavelength. This wavelength has a high water absorption coefficient, which produces rapid heating and a sharply delineated ablation zone.
Note the minimally distorted skull and brain anatomy in 2A and 2B compared to images in Figure 1B,D

time, with 46 and 34 weeks for the fluorescein and non-fluorescein
groups, respectively.

49

progression allowed visualization of arterial macrovessels within

Better GTR under fluorescein-guided GBM

the lesion with a rapid venous phase composed of multiple veins

resection was also reported by Neira JA et al.50 If and when ap-

aiming toward the periventricular zone. 23 With confirmation by

proved, fluorescein can provide another tumor vascular permeabil-

larger cohort studies, iCEUS can be a valuable tool in GBM surgery

ity-based, intraoperative tracer in GBM resection.

and tumor vascular visualization.

We note here that although both 5-ALA and fluorescein are
fluorescent, there are some important differences between them.
Fluorescein is seen primarily as a marker for contrast leakage so it
can act as a surrogate for contrast enhancement. 5-ALA is a met-

6 | L A S E R I NTE R S TITI A L TH E R M A L
TH E R A PY

abolic marker. This is borne out by the fact that while the positive
predictive value (PPV) for fluorescence is very high (essentially

Recently, laser interstitial thermal therapy (LITT) has emerged as a

100%), the negative predictive value (NPV) is very low (more like

minimally invasive technique to treat brain tumors. 54-59 Through the

20%). This is reflective of the both local and diffuse nature of gliomas

use of MR thermometry, tumor ablation can be tracked in real time,

with high-grade (high fluorescence) tumor in the area of contrast en-

thus obtaining precise margins with prompt recovery and minimal

hancement, whereas the non-fluorescent areas will still have tumor

surgical side effects when compared to traditional techniques.60-63

tissue, but in lower concentration and lower grade.

Accordingly, this technique is often used for recurrent brain tumors

Ultrasound is a low cost, portable imaging modality with a

and for primary tumors in locations where conventional techniques

long history of successful applications in various organ systems.

might leave the patient with profound disability. In the post-LITT pe-

iUS is reported to be useful in brain and spinal tumor surgery and

riod, the rim of tissue around the ablation periphery is reported to

assists in increasing GTR and EOR. 51 Increased survival (11.9 as

develop a relatively long-lasting (several weeks) and localized BBB

opposed to 9.6 months) was found after retrospective analysis in

breakdown, as evidenced by a characteristic rim contrast enhance-

one study.

52

Notably, Jakola et al reported that the use of iUS was

associated with better quality of life in glioma patients.

53

ment on post-ablation T1-weighted MRI.64,65 LITT is reliant on iMRI

The effi-

for laser fiber insertion into the tumor core and for monitoring the

cacy of iUS can be improved by using iCEUS. This technique uses

extent of ablation in real time. It also has the advantages of being

microbubbles injected intravenously just before beginning the

minimally invasive (a small burr hole made for the laser fiber in con-

imaging procedure and increases EOR as well as provides a bet-

trast to a craniotomy for traditional resection), quicker recovery time

ter detailed picture of tumor-associated microvasculature. 23 In a

and shorter hospital stay for the patient. With the absence of crani-

prospective study of 10 patients, these authors observed that the

otomy and dural opening, tissue shifts due to cerebrospinal fluid loss

use of CEUS before, during, and after surgery helped in tumor lo-

are also minimized and the iMRI is likely to have a greater degree of

calization, maximizing GBM resection. The iCEUS images could be

agreement with pre-surgical scans in determining glioma debulking

superimposed over preoperative MR images for confirmation and

limits.

resected tumoral areas were confirmed by histopathology for the

LITT is increasingly being used for cytoreductive surgery in recur-

presence of tumor tissue. In addition, the contrast enhancement

rent glioma. It relies on a stereotactically guided laser probe to deliver

6 of 9
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heat in a controlled manner and ablate the surrounding tumor tissue
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(Figure 2A,B). Uniquely, LITT uses MR thermometry which allows
the expansion of the ablation to be closely monitored in real time

It is now recognized that just like a combination of treatments for GBM,

(Figure 1C), thereby sparing surrounding brain tissue.66 Of particular

also needed is a combination of multimodal, intraoperative imaging

importance, MRI after LITT demonstrates post-contrast enhance-

techniques to achieve as complete a tumor resection as safely possible.

ment in the periphery of tissue ablation zones. Within the ablation

Several such techniques that exploit the microvascular alterations in

zone, the tissue undergoes coagulative necrosis, which is thus imper-

GBM are available and are being continually optimized for intraopera-

meable, as evidenced by the lack of contrast enhancement in the core.

tive applications. The techniques described above utilize GBM vascular

However, the temperature achieved (about 40–43°C) in the perile-

flow, permeability or other functional alterations to assist in intraopera-

sional zone is not high enough to cause cell death, but does result in

tive visualization for increasing resection efficacy. However, more re-

disruption of the BBB (Figure 2B). LITT is also the GBM cytoreductive

search needs to be done for a better understanding of the relationship

procedure with a specific, relatively long-lasting effect on peri-tu-

between the tumor and surrounding normal brain tissue, microcircu-

moral BBB permeability. This raises the question as to whether LITT

lation and their interactions to develop technologies and tracers with

breaks down the BBB sufficiently to deliver chemotherapy agents in

high specificity and sensitivity. In addition, standardization of image ac-

useful concentrations to the surrounding brain. Available published

quisition and analysis techniques for various MRI parameters needs to

reports are supportive. For instance, in a rodent model, heating by a

be achieved for efficient monitoring of resection as well as treatment

Nd-Yag laser resulted in increased diffusion of Evans blue (a fluores-

efficacy and their inter-institute comparisons.88 For instance, note the

cent dye often used to visualize BBB breakdown) and paclitaxel in the

effects of bevacizumab on GBM. The drug led to acutely decreased con-

vicinity.67 Similarly, in microwave-induced hyperthermia in monkeys,

trast enhancement, but that did not represent true tumor response. The

a ring of contrast enhancement appeared on MRI, confirmed as dis-

decrease represented lowered BBB/BTB permeability and potentially

ruption of the BBB by extravasation of Evans blue.68 Other studies

the switch of the tumor growth pattern to an infiltrative, non-enhancing

have examined methods for BBB disruption, for example, radiofre-

phenotype.89 The recently described DCE-MRI parameters that repre-

69

quency ablation to cause local heating of brain tissue ; more recent

sent several, inter-dependent, concurrently measured parameters may

studies using lasers have demonstrated transient disruption of the

be of help in resolving such false-positive results.30 Drug delivery to

70

BBB in an animal model

and after LITT in humans.

65

gliomas remains a challenge. A greater understanding of permeability
alterations and vascular adaptation changes in tumoral and peri-tumoral

7
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cerebral microvasculature is crucial to overcome this obstacle to effec-

G LI O M A D RU G D E LI V E RY

tive treatment.

Even in cases of surgical resection with maximal removal of the con-

AC K N OW L E D G E M E N T S

trast-enhancing lesion, infiltrative tumor cells reside in the peripheral

The authors thank Susan MacPhee for editorial assistance. Both the

margin. However, the BBB, which functions to protect the brain from

authors of this review paper have read and agree with the contents

foreign substrates, is mostly intact following surgery. Nearly 98% of

of this manuscript. This work was supported by a Henry Ford Health

small molecule drugs and all large molecule drugs do not cross the

System Physician-Scientist Grant A20050 (IYL). TNN is partly sup-

BBB.71-74 Thus, inadequate drug delivery to the brain is a major limiting

ported by R01CA218596 (Ewing, James R. and Brown, Stephen L.).

factor in the treatment of HGG.9,75 Several different approaches are
being tried to enhance drug delivery to the brain.76 They include transient opening of the BBB via infusion of hyperosmotic mannitol,

77
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fo-

TNN declares no conflicts of interest. IYL has consulting agreements

cused ultrasound,78,79 Trojan horse approach via endothelial transferrin

with Medtronic, Inc., Minneapolis, MN, USA, and Monteris Medical,

receptors74 and ultrashort pulsed laser.80 A promising clinical treatment

Inc., Plymouth, MN, USA.

is osmotic BBB opening using intra-arterial mannitol infusion.81 A bolus
of mannitol is infused via either internal carotid or vertebral artery to
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transiently and unilaterally open the BBB for chemotherapy delivery in

Data presented in Figure 1 of this manuscript are from the senior au-

this technique. It has been successfully used in the treatment of pri-

thor's own previous publication available on public domain. Data in

mary central nervous system lymphoma and other brain tumors with

Figure 2 are unpublished and available as part of the data repository

82

intraoperative monitoring to confirm BBB opening. Yet, drug delivery

in the Department of Neurosurgery.

to a large number of primary, recurrent and metastatic brain tumors to
achieve durable response remains a challenge.76,83-85 There is benefit
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to circumventing the BBB as demonstrated by the therapeutic effects
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of inserting carmustine-impregnated polymer wafers (Gliadel) into the
surgical cavity.86,87 LITT-induced transient BBB opening observed in
GBM assumes significance in furthering such efforts to overcome the
BBB for effective glioma drug delivery.
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